Boehringer Ingelheim says the recently-announced extension of its three-old collaboration with University of Dundee to develop new treatments targeting cancer-causing proteins reflects a commitment to open innovation as well as its ongoing focus on developing oncology as a therapeutic area . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge